Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

<< Previous

Bullboard Posts

Next >>

Post by Oden6570on Jul 31, 2024 7:42am

249 Views

Post# 36155754

Trinuclear ruthenium(II) polypyridyl complexes:

The development of new chemotherapeutic treatments to circumvent drug resistance for long-term use, has become one of the important research thrusts in the battle against cancer. Since the discovery of cisplatin, several platinum-based metallodrugs have been developed, including the clinically used carboplatin and oxaliplatin [1,2]. However, the use of these metallodrugs is hindered by the same hurdles that limit the application of cisplatin, including off-target effects, the development of tumour drug resistance and a limited range of activity [3,4]. These limitations have resulted in a redirection in metallodrug discovery to other platinum-group metals, with ruthenium-based complexes representing the vanguard of research into the development of metallodrugs based on alternative platinum-group metals. This is exemplified by several ruthenium-based complexes including NAMI-A, NKP-1339 and TLD1433 having been clinically investigated for the treatment of various cancers
Trinuclear ruthenium(II) polypyridyl complexes: Evaluation as photosensitizers for enhanced cervical cancer treatment - ScienceDirect

<< Previous

Bullboard Posts

Next >>

Brianne Gardner's 2025 stock picks